Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 63, Issue 9, 2004, Pages 1056-1061

  Kraan, M C ^a   Smeets, T J M ^a   Van Loon, M J ^a   Breedveld, F C ^b   Dijkmans, B A C ^c   Tak, P P ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; DRUG METABOLITE; GAMMA INTERFERON; INTERLEUKIN 6; LEFLUNOMIDE; METHOTREXATE; PYRIMIDINE; TERIFLUNOMIDE; URIDINE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CELL ISOLATION; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOUBLE BLIND PROCEDURE; DRUG INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL LYMPHOCYTE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PYRIMIDINE SYNTHESIS; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ADULT; AGED; ANILINE COMPOUNDS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CELL DIVISION; CELLS, CULTURED; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; HUMANS; HYDROXYBUTYRATES; IMMUNOSUPPRESSIVE AGENTS; INTERFERON TYPE II; INTERLEUKIN-6; ISOXAZOLES; METHOTREXATE; MIDDLE AGED;

EID: 4344694414     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2003.014738     Document Type: Article

References (33)

1. Weinblatt ME, Kremer JM, Coblyn JS, Maier AL, Helfgott SM, Morrell M, et al. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 1999;7:1322-8.
2. Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 1999;159:2542-50.
3. Kraan MC, Reece RJ, Barg EC, Smeets TJM, Farnell J, Rosenburg R, et al. Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers. Arthritis Rheum 2000;8:1820-30.
4. Fox RI, Herrmann ML, Frangou CG, Wahl GM, Morris RE, Strand V, et al. Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol 1999;93:198-208.
5. Breedveld FC, Dayer JM. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis 2000;59:841-9.
6. Herrmann ML, Schleyerbach R, Kirschbaum BJ. Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases. Immunopharmacology 2000;47:273-89.
7. Ruckemann K, Fairbanks LD, Carrey EA, Hawrylowicz CM, Richards DF, Kirschbaum B, et al. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans. J Biol Chem 1998;34:21682-91.
8. Chong ASF, Finnegan A, Jiang X, Gebel H, Sankary HN, Foster P, et al. Leflunomide, a novel immunosuppressive agent. The mechanism of inhibition of T cell proliferation. Transplantation 1993;55:1361-6.
9. Siemasko K, Chong AS, Jack HM, Gong H, Williams JW, Finnegan A. Inhibition of JAK3 and STAT6 tyrosine pnosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production. J Immunol 1998;4:1581-8.
10. Manna SK, Aggarwal BB. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kB activation and gene expression. J Immunol 1999;162:2095-102.
11. Hoskin DW, Taylor RM, Makrigiannis AP, James H, Lee TD. Dose-dependent enhancing and inhibitory effects of A77 1726 (leflunomide) on cytotoxic T lymphocyte induction. Int J Immunopharmacol 1998;20:505-13.
12. Deage V, Burger D, Dayer JM. Exposure of T lymphocytes to leflunomide but not to dexamethasone favors the production by monocytic cells of interleukin-1 receptor antagonist and the tissue-inhibitor of metalloproteinases-1 over that of interleukin-1 beta and metalloproteinases. Eur Cytokine Netw 1998;4:663-8.
13. Kraan MC, de Koster BM, Elferink JG, Post WJ, Breedveld, FC, Tak PP. Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis: findings in a prospective, randomized, double-blind clinical trial in fifteen patients. Arthritis Rheum 2000;43:1488-95.
14. Barrera P, Haagsma CJ, Boerbooms AM, van Riel PL, Borm GF, van de Putte LB, et al. Effect of methotrexate alone or in combination with sulphasalazine on the production and circulating concentrations of cytokines and their antagonists. Longitudinal evaluation in patients with rheumatoid arthritis. Br J Rheumatol 1995;34:747-55.
15. Schuerwegh AJ, van Offel JF, Bridts CH, Stevens WJ, de Clerck LS. Influence of longterm therapy with methotrexate and low dose corticosteroids on type 1 and type 2 cytokine production in CD4+ and CD8+ T lymphocytes of patients with rheumatoid arthritis. J Rheumatol 2001;28:1793-9.
16. Emery P, Breedveld FC, Lemmel EM, Kaltwasser JP, Dawes PT, Gonnor B. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000;39:655-65.
17. Kloppenburg M, Brinkman BM, Rooij-Dijk HH, Miltenburg AM, Daha MR, Breedveld FC, et al. The tetracycline derivative minocycline differentially affects cytokine production by monocytes and T lymphocytes. Antimicrob Agents Chemother 1996;40:934-40.
18. Smolen JS, Emery P. Efficacy and safety of leflunomide in active rheumatoid arthritis. Rheumatology (Oxford) 2000;39(suppl 1):48-56.
19. Morris RE. New small molecule immunosuppressants for transplantation: review of essential concepts. J Heart Lung Transplant 1993;12:S275-86.
20. Zielinski T, Muller HJ, Bartlett RR. Effects of leflunomide (HWA 480) on expression of lymphocyte activation markers. Agents Actions 1993;38(Spec No):C80-2.
21. Lang R, Wagner H, Heeg K. Differential effects of the immunosuppressive agents cyclosporine and leflunomide in vivo - leflunomide blocks clonal T cell expansion yet allows production of lymphokines and manifestation of T cell-mediated shock. Transplantation 1995;59:382-9.
22. Straub RH, Muller-Ladner U, Lichtinger T, Scholmerich J, Menninger H, Lang B. Decrease of interleukin 6 during the first 12 months is a prognostic marker for clinical outcome during 36 months treatment with disease-modifying anti-rheumatic drugs. Br J Rheumatol 1997;36:1298-303.
23. Wascher TC, Hermann J, Brezinschek R, Brezinschek HP, Wilders-Truschnig M, Rainer F, et al. Serum levels of interleukin-6 and tumour-necrosis-factor- alpha are not correlated to disease activity in patients with rheumatoid arthritis after treatment with low-dose methotrexate. Eur J Clin Invest 1994;24:73-5.
24. Bhardwaj N, Santhanam U, Lau LL, Tatter SB, Ghrayeb J, Rivelis M, et al. IL-6/IFN-beta 2 in synovial effusions of patients with rheumatoid arthritis and other arthritides. Identification of several isoforms and studies of cellular sources. J Immunol 1989;143:2153-9.
25. Hoskin DW, Taylor RM, Makrigiannis AP, James H, Lee TD. Dose-dependent enhancing and inhibitory effects of A77 1726 (leflunomide) on cytotoxic T lymphocyte induction. Int J Immunopharmacol 1998;20:505-13.
26. Jankovic V, Samardzic T, Stosic-Grujicic S, Popadic D, Trajkovic V. Cell-specific inhibition of inducible nitric oxide synthase activation by leflunomide. Cell Immunol 2000;199:73-80.
27. Manna SK, Mukhopadhyay A, Aggarwal BB. Leflunomide suppresses TNF-induced cellular responses: effects on NF-kappa B, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis. J Immunol 2000;165:5962-9.
28. Rozman B. Clinical pharmacokinetics of leflunomide. Clin Pharmacokinet 2002;41:421-30.
29. Gerards AH, de Lathouder S, de Groot ER, Dijkmans BA, Aarden LA. Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis. Rheumatology (Oxford) 2003;42:1189-96.
30. de Lathouder S, Gerards AH, de Groot ER, Valkhof M, Aarden LA. Mycophenolic acid and methotrexate inhibit lymphocyte cytokine production via different mechanisms. Eur Cytokine Netw 2002;13:317-23.
31. van Ede AE, Laan RF, De Abreu RA, Stegeman AB, van de Putte LB. Purine enzymes in patients with rheumatoid arthritis treated with methotrexate. Ann Rheum Dis 2002;61:1060-4.
32. Montesinos MC, Desai A, Delano D, Chen JF, Fink JS, Jacobson MA, et al. Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. Arthritis Rheum 2003;48:240-7.
33. Chan ES, Cronstein BN. Molecular action of methotrexate in inflammatory diseases. Arthritis Res 2002;4:266-73.